Evaluation of calcium gluconate on reduction of abdominal pain caused by lead toxicity

The effect of intravenous calcium gluconate on abdominal pain among oral opium users suspected to lead poisoning

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171009036661N2

Enrollment

Registered

2018-05-27

Start date

2017-06-02

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lead toxicity in opium addicted patients.

Interventions

Intervention 1: Intervention group: Patients who underwent cardiac monitoring and pulsed oximetry of 10cc calcium gluconate after injection of morphine with a microtiter. Before injection, the VAS is

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: People over 18 years old Oral users of opioids with a lead level greater than 20

Exclusion criteria

Exclusion criteria: 1. Mental retardation Neuropathic diseases such as diabetes Chronic pain syndromes High blood pressure and heart disease Contraindications for calcium gluconate injection, including sensitivity to this group of drugs. Kidney stones. Hypercalcemia. Hypophosphatemia. pregnant patient Patient with Asthma Patients suspected of obstructive bowel obstruction or with acute abdominal symptoms Other diagnosis other than lead poisoning Use of psychiatric drugs Chronic severe History of Morphine Sensitivity

Design outcomes

Primary

Measure	Time frame
Lead colic. Timepoint: 15 minutes, 30 minutes and an hour later. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Massoud mayel

Kerman University of Medical Sciences

masoud.mayel@gmail.com+98 34 3223 5011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 28, 2026